IDH1 and acute myeloid leukemia: Lastly, with the more recent advances in R/R AML regarding targeted therapies for markers such as IDH1/2, FLT3, and CD33, it is acknowledged that some patients may benefit from targeted therapies rather than the presently studied cytotoxic regimens.